Last update: Jan. 29, 2017

Ketotifen Fumarate

Low Risk for breastfeeding


Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

1st-generation-antihistamine and piperidine-type drug with a minimal sedative effect.
Indicated on prophylaxis of asthma, rhinitis (oral administration) and conjunctivitis (administrated as eye drops).

At latest update relevant published data on excretion into breast milk were not found.
Pharmacokinetic data (large volume of distribution and moderately high molecular weight) make it unlikely that significant amounts of milk would pass through breastmilk.
Plasma levels following ophthalmic administration are undetectable (AEMPS 2011).
It is a medicine authorized for use in infants from 6 months of age on.
It does not influence prolactin levels (Dolecek 1984).

Until more published data on this drug related to breastfeeding is available, a safer and known alternative should be preferred during the neonatal period and in case of prematurity.
Ophthalmic administration is safe while breastfeeding.

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Ketotifen Fumarate in other languages or writings:

Groups

Ketotifen Fumarate belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Ketotifen Fumarate in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 50 %
Molecular weight 426 daltons
Protein Binding 75 %
VD 56 l/Kg
Tmax 2 - 4 hours
T1/2 12 (7 - 27) hours

References

  1. AEMPS. Ketotifeno oral Ficha técnica. 2015 Full text (in our servers)
  2. AEMPS. Ketotifeno colirio Ficha técnica. 2011 Full text (in our servers)
  3. Novartis. Ketotifen (Zaditen). Drug Summary. 2011 Full text (in our servers)
  4. Grahnén A, Lönnebo A, Beck O, Eckernäs SA, Dahlström B, Lindström B. Pharmacokinetics of ketotifen after oral administration to healthy male subjects. Biopharm Drug Dispos. 1992 Abstract
  5. Dolecek R, Janstová V, Halatová A. Growth hormone plasma levels in children treated for 6 months with ketotifen. Pharmatherapeutica. 1984 Abstract

Total visits

15,180

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) from Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM